Contipharma reaches a new major milestone in its development by obtaining the international ISO 13485 certification.
This recognition attests to the compliance of the company’s quality management system for the design, development, and distribution of in vitro diagnostic devices.
“This certification confirms our ability to develop and deploy medical solutions that meet the highest requirements for safety, traceability, and regulatory compliance,” emphasizes Bernard Delhez, CEO and Founder of Contipharma.
Specializing in the development of next-generation non-invasive diagnostics, Contipharma is committed to making innovation accessible where needs are most urgent—particularly in countries facing resource shortages or epidemic emergencies.
“Quality is not a constraint, but a lever for responsible innovation,” adds Hope Sounouvou, Research Director. He specifically mentions the LAMPOX™ test, a fast and reliable solution for detecting the virus responsible for Mpox, designed for direct use in the field.
With this ISO 13485 certification, Contipharma strengthens its credibility with partners, regulatory authorities, and investors, and confirms its mission: putting science and quality at the service of healthcare systems and patients.
